| Electroconvulsive seizures regulate gene expression of distinct neurotrophic signaling pathways CA Altar, P Laeng, LW Jurata, JA Brockman, A Lemire, J Bullard, ... Journal of Neuroscience 24 (11), 2667-2677, 2004 | 405 | 2004 |
| Simultaneous determination of 3, 4‐dihydroxyphenylalanine, 5‐hydroxytryptophan, dopamine, 4‐hydroxy‐3‐methoxyphenylalanine, norepinephrine, 3, 4‐dihydroxyphenylacetic acid … J Wagner, P Vitali, MG Palfreyman, M Zraika, S Huot Journal of neurochemistry 38 (5), 1241-1254, 1982 | 362 | 1982 |
| The role of 5-HT2A receptors in antipsychotic activity CJ Schmidt, SM Sorensen, JH Kenne, AA Carr, MG Palfreyman Life sciences 56 (25), 2209-2222, 1995 | 313 | 1995 |
| The relationship between GABA concentrations in brain and cerebrospinal fluid P Böhlen, S Huot, MG Palfreyman Brain research 167 (2), 297-305, 1979 | 215 | 1979 |
| NMDA receptor complex antagonists have potential anxiolytic effects as measured with separation-induced ultrasonic vocalizations JH Kehne, TC McCloskey, BM Baron, EM Chi, BL Harrison, JP Whitten, ... European journal of pharmacology 193 (3), 283-292, 1991 | 164 | 1991 |
| Normalizing effects of EVP-6124, an alpha-7 nicotinic partial agonist, on event-related potentials and cognition: a proof of concept, randomized trial in patients with … SH Preskorn, M Gawryl, N Dgetluck, M Palfreyman, LO Bauer, DC Hilt Journal of Psychiatric Practice® 20 (1), 12-24, 2014 | 157 | 2014 |
| Enzyme-activated irreversible inhibitors of monoamine oxidase: phenylallylamine structure-activity relationships IA McDonald, JM Lacoste, P Bey, MG Palfreyman, M Zreika Journal of medicinal chemistry 28 (2), 186-193, 1985 | 153 | 1985 |
| Electrophysiological, biochemical and behavioral evidence for 5-HT2 and 5-HT3 mediated control of dopaminergic function MG Palfreyman, CJ Schmidt, SM Sorensen, MW Dudley, JH Kehne, ... Psychopharmacology 112, S60-S67, 1993 | 148 | 1993 |
| The pharmacology of GABA-transaminase inhibitors MG Palfreyman, PJ Schechter, WR Buckett, GP Tell, J Koch-Weser Biochemical pharmacology 30 (8), 817-824, 1981 | 145 | 1981 |
| Activity of 5, 7-dichlorokynurenic acid, a potent antagonist at the N-methyl-D-aspartate receptor-associated glycine binding site. BM Baron, BL Harrison, FP Miller, IA McDonald, FG Salituro, CJ Schmidt, ... Molecular Pharmacology 38 (4), 554-561, 1990 | 141 | 1990 |
| Determination of DOPA, dopamine, DOPAC, epinephrine, norepinephrine, α-monofluoromethyldopa and α-difluoromethyldopa in various tissues of mice and rats using reversed-phase … J Wagner, M Palfreyman, M Zraika Journal of Chromatography B: Biomedical Sciences and Applications 164 (1), 41-54, 1979 | 132 | 1979 |
| Effect of acute and chronic MDL 73,147 EF, a 5-HT3 receptor antagonist, on A9 and A10 dopamine neurons SM Sorensen, TM Humphreys, MG Palfreyman European journal of pharmacology 163 (1), 115-118, 1989 | 105 | 1989 |
| Inhibitors of lysyl oxidase MG Palfreyman, P Bey, IA McDonald US Patent 4,965,288, 1990 | 91 | 1990 |
| History of serotonin and serotonin disorders. A Sjoerdsma, MG Palfreyman Annals of the New York Academy of Sciences, 1990 | 83 | 1990 |
| [3H] 5, 7-Dichlorokynurenic acid, a novel radioligand labels NMDA receptor-associated glycine binding sites BM Baron, BW Siegel, AL Slone, BL Harrison, MG Palfreyman, SD Hurt European Journal of Pharmacology: Molecular Pharmacology 206 (2), 149-154, 1991 | 80 | 1991 |
| Relationship between extracellular 5‐hydroxytryptamine and behaviour following monoamine oxidase inhibition and l‐tryptophan AJ Sleight, CA Marsden, KF Martin, MG Palfreyman British journal of pharmacology 93 (2), 303-310, 1988 | 78 | 1988 |
| Inhibitors of lysyl oxidase MG Palfreyman, P Bey, IA McDonald US Patent 5,021,456, 1991 | 72 | 1991 |
| (E)-. beta.-(Fluoromethylene)-m-tyrosine: a substrate for aromatic L-amino acid decarboxylase liberating an enzyme-activated irreversible inhibitor of monoamine oxidase IA McDonald, JM Lacoste, P Bey, J Wagner, M Zreika, MG Palfreyman Journal of the American Chemical Society 106 (11), 3354-3356, 1984 | 70 | 1984 |
| Inhibition of monoamine synthesis by irreversible blockade of aromatic aminoacid decarboxylase with α-monofluoromethyldopa MJ Jung, MG Palfreyman, J Wagner, P Bey, G Ribereau-Gayon, M Zraika, ... Life sciences 24 (11), 1037-1042, 1979 | 67 | 1979 |
| (E)-2-(3, 4-dimethoxyphenyl)-3-fluoroallylamine: a selective, enzyme-activated inhibitor of type B monoamine oxidase P Bey, J Fozard, JM Lacoste, IA McDonald, M Zreika, MG Palfreyman Journal of medicinal chemistry 27 (1), 9-10, 1984 | 65 | 1984 |
